ACTION OF LOVASTATIN IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULAR SCLEROSIS

洛伐他汀对局灶节段性肾小球硬化症患者的作用

• 批准号: 6244189
• 负责人: GUSTAV SCHONFELD
• 金额: $ 2.25万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244189
• 关键词: blood lipid; blood lipoprotein metabolism; clinical research; glomerulosclerosis; human subject; lovastatin; low density lipoprotein; pharmacokinetics; very low density lipoprotein

Lovastatin decreases plasma lipid levels in patients with FSGS BY inhibiting VLDL production and/or enhancing VLDL, IDL, and LDL elimination.

洛伐他汀可降低 FSGS BY 患者的血脂水平 抑制 VLDL 产生和/或增强 VLDL、IDL 和 LDL 消除。